NGFR and Alzheimer disease: Finally, the use of NGFR/p75NTR antagonist molecules or the administration of NGFR/p75NTR ECD appear to be promising therapeutic approaches for AD; a phase II clinical trial is currently underway on mild–moderate AD patients with the use of the small NGFR/p75NTR ligand LM11A-31.